Novo Nordisk has entered a multi-year collaboration with Replicate Bioscience to develop novel therapies for obesity, type 2 diabetes, and cardiometabolic diseases utilizing Replicate's self-replicating RNA (srRNA) platform. The partnership could deliver up to $550 million in payments plus royalties. Replicate's generative AI-powered srRNA technology enables efficient cellular production of therapeutic proteins with enhanced durability. This alliance complements Novo's ongoing expansion of its cardiometabolic drug pipeline, aiming to build on the success of medications like Ozempic and Wegovy.